50896-91-8

Upstream product

• 50722-31-1 1-(3-benzyloxy-4-methoxy-benzyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline 
• 6429-04-5 1,2,3,4-tetrahydro-1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride 
• 75608-42-3 N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(3-hydroxy-4-methoxyphenyl)acetamide 
• 1131-94-8 homoisovanillic acid 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 179260-96-9 4-methoxy-3-(triisopropylsilyloxy)-benzaldehyde 
• 1210-57-7 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-1-carbonitrile 
• 1344118-29-1 1-(4-methoxy-3-triisopropylsilyloxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 1344118-32-6 4-methoxy-3-(triisopropylsilanyloxy)benzyl bromide 
• 1356165-40-6 4-methoxy-3-(triisopropylsilyloxy)benzyl alcohol 
• 1356165-29-1 1-(4-methoxy-3-triisopropylsilyloxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 53898-95-6 C₁₉H₂₁NO₄ 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

1,3-benzyl migration in iminium ions: Evidence for a fast free-radical chain reaction

The "exocyclic" 1,3-benzyl shift observed in iminium salts derived from 1-benzyl-1,2,3,4-tetrahydroisoquinolines is related to the "endocyclic" Knabe rearrangement. A crossover experiment, isotopic labelling, the study of initiators and inhibitors as well as DFT calculations of gas-phase model structures provide evidence for a free-radical pathway under kinetic entropy control that is not affected by "slow" radical traps. An unexpected rearrangement of methyleneiminium ions derived from 1-benzyl-1,2,3,4-tetrahydroisoquinolines has been investigated by isotopic labelling, trapping experiments and DFT calculations. Theobserved benzyl migration proceeds by an exceptionally fast radical chain reaction closely related to the Knabe reaction.Remarkably, the process is inhibited byneither methyl acrylate nor dioxygen. Copyright

CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS

The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.

COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS

Compositions comprising extracts or isolated or purified compounds from plants of the genus Corydalis provide prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Corydalis compounds and their derivatives of natural and synthetic origins lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression and activate AMP-activated protein kinase. Specific stereoisomers of Corydalis compounds with lipid lowering activity include 14R-(+)-corypalmine, 14R,13S-(+)-corydaline, 14R-(+)-tetrahydropalmatin, (+)-corlumidin, d-(+)-bicuculline, and (+)-egenine.

Structural analyses of metabolites of phenolic 1- benzyltetrahydroisoquinolines in plant cell cultures by LC/NMR, LC/MS, and LC/CD

The metabolism of the phenolic 1-benzyltetrahydroisoquinoline alkaloids was studied in cell cultures of Macleaya and Corydalis species. The crude alkaloid fraction obtained from feeding experiments was investigated by application of the combined LC/NMR and LC/APCI-MS (/MS) techniques. Several metabolites were detected, and their structures (6 and 8-14) were identified. Bioconversion of the phenolic 1-benzyltetrahydroisoquinoline (2) into the pseudoprotoberberine (8) was demonstrated for the first time. LC/APCI-MS and LC/CD experiments carried out on a chiral column permitted the deduction of the major enantiomeric form of the chiral metabolites. Thus, the combination of NMR, MS, and CD data permitted the structural elucidation and stereochemical analysis of the metabolites in the extract matrix solution, without isolation and sample purification prior to the coupling experiments.